share_log
Breakings ·  Sep 28 04:30
Carvykti® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients With Multiple Myeloma as Early as Second Line
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment